Human papillomavirus type 6 L1 capsid protein antigen

Identification

Brand Names

Gardasil, Gardasil 9

Generic Name

Human papillomavirus type 6 L1 capsid protein antigen

DrugBank Accession Number

DB10299

Background

Human papillomavirus type 6 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant Saccharomyces cerevisiae and self-assembled into VLPs.

Type

Biotech

Groups

Approved, Investigational

Biologic Classification

Vaccines
Other vaccines

Synonyms

• L1 protein, Human papillomavirus type 6 Vaccine
• Recombinant human papillomavirus type 6 L1 protein

Pharmacology

Indication

Not Available

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

• Human Papillomavirus (HPV) Infections
• Infection caused by human papillomavirus type 6

Contraindications & Blackbox Warnings

Avoid life-threatening adverse drug events

Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events & improve clinical decision support.

Learn more

Pharmacodynamics

Not Available

Mechanism of action

Not Available

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

Learn more

Improve decision support & research outcomes with our structured adverse effects data.

Learn more

Toxicity

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Not Available

Food Interactions

Not Available

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
Gardasil	Human papillomavirus type 6 L1 capsid protein antigen (20 ug/0.5mL) + Human papillomavirus type 11 L1 capsid protein antigen (40 ug/0.5mL) + Human papillomavirus type 16 L1 capsid protein antigen (40 ug/0.5mL) + Human papillomavirus type 18 L1 capsid protein antigen (20 ug/0.5mL)	Injection, suspension	Intramuscular	Merck Sharp & Dohme Llc	2006-06-08	Not applicable
Gardasil	Human papillomavirus type 6 L1 capsid protein antigen (20 mcg) + Human papillomavirus type 11 L1 capsid protein antigen (40 mcg) + Human papillomavirus type 16 L1 capsid protein antigen (40 mcg) + Human papillomavirus type 18 L1 capsid protein antigen (20 mcg)	Injection, suspension	Intramuscular	Merck Sharp & Dohme B.V.	2021-03-18	Not applicable
Gardasil	Human papillomavirus type 6 L1 capsid protein antigen (20 mcg) + Human papillomavirus type 11 L1 capsid protein antigen (40 mcg) + Human papillomavirus type 16 L1 capsid protein antigen (40 mcg) + Human papillomavirus type 18 L1 capsid protein antigen (20 mcg)	Injection, suspension	Intramuscular	Merck Sharp & Dohme B.V.	2021-03-18	Not applicable
Gardasil	Human papillomavirus type 6 L1 capsid protein antigen (20 mcg) + Human papillomavirus type 11 L1 capsid protein antigen (40 mcg) + Human papillomavirus type 16 L1 capsid protein antigen (40 mcg) + Human papillomavirus type 18 L1 capsid protein antigen (20 mcg)	Injection, suspension	Intramuscular	Merck Sharp & Dohme B.V.	2021-03-18	Not applicable
Gardasil	Human papillomavirus type 6 L1 capsid protein antigen (20 mcg) + Human papillomavirus type 11 L1 capsid protein antigen (40 mcg) + Human papillomavirus type 16 L1 capsid protein antigen (40 mcg) + Human papillomavirus type 18 L1 capsid protein antigen (20 mcg)	Injection, suspension	Intramuscular	Merck Sharp & Dohme B.V.	2021-03-18	Not applicable
Gardasil	Human papillomavirus type 6 L1 capsid protein antigen (20 mcg) + Human papillomavirus type 11 L1 capsid protein antigen (40 mcg) + Human papillomavirus type 16 L1 capsid protein antigen (40 mcg) + Human papillomavirus type 18 L1 capsid protein antigen (20 mcg)	Injection, suspension	Intramuscular	Merck Sharp & Dohme B.V.	2021-03-18	Not applicable
Gardasil	Human papillomavirus type 6 L1 capsid protein antigen (20 ug/0.5mL) + Human papillomavirus type 11 L1 capsid protein antigen (40 ug/0.5mL) + Human papillomavirus type 16 L1 capsid protein antigen (40 ug/0.5mL) + Human papillomavirus type 18 L1 capsid protein antigen (20 ug/0.5mL)	Injection, suspension	Intramuscular	A-S Medication Solutions	2006-06-08	Not applicable
Gardasil	Human papillomavirus type 6 L1 capsid protein antigen (20 mcg) + Human papillomavirus type 11 L1 capsid protein antigen (40 mcg) + Human papillomavirus type 16 L1 capsid protein antigen (40 mcg) + Human papillomavirus type 18 L1 capsid protein antigen (20 mcg)	Injection, suspension	Intramuscular	Merck Sharp & Dohme B.V.	2021-03-18	Not applicable
GARDASIL	Human papillomavirus type 6 L1 capsid protein antigen (20.000 mcg) + Human papillomavirus type 11 L1 capsid protein antigen (40.000 mcg) + Human papillomavirus type 16 L1 capsid protein antigen (40.000 mcg) + Human papillomavirus type 18 L1 capsid protein antigen (20.000 mcg)	Suspension	Parenteral		2006-06-01	2011-06-01
Gardasil	Human papillomavirus type 6 L1 capsid protein antigen (20 mcg) + Human papillomavirus type 11 L1 capsid protein antigen (40 mcg) + Human papillomavirus type 16 L1 capsid protein antigen (40 mcg) + Human papillomavirus type 18 L1 capsid protein antigen (20 mcg)	Injection, suspension	Intramuscular	Merck Sharp & Dohme B.V.	2021-03-18	Not applicable

Categories

Drug Categories

• Actively Acquired Immunity
• Cancer immunotherapy
• Immunotherapy
• Inactivated Human Papillomavirus Vaccine

Classification

Not classified

Affected organisms

Not Available

Chemical Identifiers

UNII

61746O90DY

CAS number

Not Available

References

General References

Not Available

External Links

PubChem Substance

347910485

RxNav

798268

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Active Not Recruiting	Prevention	Allogeneic Hematopoietic Stem Cell Transplantation Recipient / Hematopoietic and Lymphoid System Neoplasm	1
4	Active Not Recruiting	Prevention	Cervical Cancer / Precancerous Cervical Lesions	1
4	Active Not Recruiting	Prevention	Cervical Carcinoma / Human Papillomavirus (HPV) Infections	1
4	Active Not Recruiting	Prevention	Coronavirus Disease 2019 (COVID‑19) / Human Papillomavirus (HPV) Infections	1
4	Active Not Recruiting	Prevention	HPV Vaccinations / Human Papilloma Virus (HPV)	1
4	Active Not Recruiting	Prevention	Human Immunodeficiency Virus (HIV) Infections / Human Papilloma Virus (HPV) / Human Papillomavirus (HPV) Vaccine	1
4	Active Not Recruiting	Prevention	Human Papilloma Virus (HPV)	1
4	Active Not Recruiting	Prevention	Human Papilloma Virus (HPV) / Vaccine Preventable Diseases	1
4	Active Not Recruiting	Prevention	Papilloma Viral Infection	1
4	Completed	Health Services Research	Cervical Intraepithelial Neoplasia (CIN) / HPV-Related Cervical Carcinoma	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Injection, suspension	Intramuscular
Suspension	Intramuscular
Suspension	Parenteral
Injection, suspension	Intramuscular; Parenteral
Injection, solution	Intramuscular
Injection, suspension	Intramuscular	40 mcg
Solution	Intramuscular
Injection
Injection, suspension

Prices

Not Available

Patents

Not Available

Properties

State

Not Available

Experimental Properties

Not Available

×

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at December 01, 2015 20:03 / Updated at February 13, 2021 10:52